Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
- 15 August 2013
- journal article
- Published by Elsevier BV in European Urology
- Vol. 65 (3), 577-584
- https://doi.org/10.1016/j.eururo.2013.08.012
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Testing for improvement in prediction model performanceStatistics in Medicine, 2013
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinomaCancer, 2008
- Sorafenib for Metastatic Renal CancerAmerican Journal of Clinical Oncology, 2008
- Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapyCancer, 2007
- Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisitedNature Reviews Cancer, 2003
- Osteoclast differentiation and activationNature, 2003
- Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’ImmunothérapieAnnals Of Oncology, 2002
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002